Fiche centre
Research Site
São Paulo — Brazil
Essais liés14clinical trials
VilleSão Paulolocalisation
PaysBrazillocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06455449
Essais cliniques associés
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ravulizumab | Maladie rénale chronique | Phase 3 | NCT05746559 | ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE | TERMINATED |
| Zibotentan/Dapagliflozin | Maladie rénale chronique | Phase 3 | NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | ACTIVE_NOT_RECRUITING |
| Anifrolumab | Myopathies | Phase 3 | NCT07691970 | ROSY-S — Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment | RECRUITING |
| Anifrolumab (blinded) | Myopathies | Phase 3 | NCT06455449 | JASMINE — A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) | RECRUITING |
| iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases | Hypertension | À vérifier | NCT03549754 | iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases | RECRUITING |
| Baxdrostat/dapagliflozin | Hypertension | Phase 3 | NCT06742723 | BaxDuo-Pacific — A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure | RECRUITING |
| Gefurulimab | Myasthénie | Phase 3 | NCT06607627 | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06627647 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05835310 | BLOSSOM — An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | RECRUITING |
| ALXN1720 | Myasthénie | Phase 3 | NCT05556096 | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Surovatamig | Lupus | Phase 1 | NCT07201558 | ASSURO — Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants | RECRUITING |
| Anifrolumab | Lupus | Phase 3 | NCT05138133 | IRIS — Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Rilvegostomig | Cancer | Phase 3 | NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | RECRUITING |
| Trastuzumab deruxtecan | Parkinson | Phase 3 | NCT06989112 | DE-01 — DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | RECRUITING |